Evaluating Immunosuppressive Effects of In Utero Exposure to Drug and Biologic Products; Public Workshop

Riepilogo

The Food and Drug Administration (FDA) is announcing the following public workshop entitled "Evaluating Immunosuppressive Effects of In Utero Exposure to Drug and Biologic Products." The purpose of the public workshop is to discuss transplacental transfer of drug and biological products with immunosuppressive properties and the potential clinical impact on the developing fetus and newborn infant, understand the gaps in knowledge, and consider innovative approaches to improve collection of relevant data.